托珠单抗治疗难治性非感染性葡萄膜炎性黄斑囊样水肿的多中心研究
这项回顾性病例系列研究评估了托珠单抗(TCZ)治疗难治性黄斑囊样水肿(CME)的疗效与安全性,共纳入25例对糖皮质激素和至少一种传统免疫抑制剂(多数还对其他生物制剂)反应不佳的非感染性葡萄膜炎继发CME患者。治疗12个月后,黄斑厚度和最佳矫正视力(BCVA)均较基线有统计学显著改善,泼尼松日剂量显著降低,14例达到缓解,仅观察到轻微副作用。结论认为TCZ可降低难治性葡萄膜炎相关CME的黄斑厚度。
要点
- TCZ治疗12个月后黄斑厚度从415.7±177.2 μm降至259.1±499.5 μm(P=.00009)。
- BCVA从0.39±0.31改善至0.54±0.33(P=.0002),泼尼松日剂量从15.9±13.6 mg降至3.1±2.3 mg(P=.002)。
- 25例中14例达到缓解,平均随访12.7±8.34个月仅见轻微副作用。
核心结论
- 在难治性非感染性葡萄膜炎相关CME患者中,托珠单抗治疗可降低黄斑厚度并改善BCVA,同时具有糖皮质激素节约效应。
研究设计与样本
- 回顾性病例系列研究,纳入25例对糖皮质激素和至少1种传统免疫抑制剂(多数对其他生物制剂)反应不佳的非感染性葡萄膜炎继发CME患者。
- CME定义为中央视网膜厚度大于300 μm,主要结局指标为黄斑厚度。
主要发现
- 治疗12个月后黄斑厚度较基线显著改善(415.7±177.2 vs 259.1±499.5 μm;P=.00009)。
- BCVA较基线显著改善(0.39±0.31 vs 0.54±0.33;P=.0002)。
- 泼尼松日剂量较基线显著降低(15.9±13.6 mg/day vs 3.1±2.3 mg/day;P=.002)。
- 25例患者中14例达到缓解,平均随访12.7±8.34个月仅观察到轻微副作用。
关键数值与推荐
- CME定义为中央视网膜厚度大于300 μm。
- 纳入标准为对糖皮质激素和至少1种传统免疫抑制剂反应不佳,且多数对其他生物制剂反应不佳。
临床怎么用
- 对于难治性非感染性葡萄膜炎相关CME,托珠单抗可作为降低黄斑厚度、改善视力并减少糖皮质激素用量的治疗选择。
局限性
- 本研究为回顾性病例系列,样本量25例,平均随访12.7±8.34个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cystoid macular edema (CME) is a leading cause of blindness. This study assessed the efficacy and safety of tocilizumab (TCZ) in refractory CME. DESIGN: Retrospective case series. METHODS: Patients with CME secondary to noninfectious uveitis who had inadequate response to corticosteroids and at least 1 conventional immunosuppressive drug, and in most cases to other biological agents, were studied. CME was defined as central retinal thickness greater than 300 μm. The primary outcome measure was macular thickness. Intraocular inflammation, best-corrected visual acuity (BCVA), and corticosteroid-sparing effect were also analyzed. RESULTS: A total of 25 patients (mean ± standard deviation age 33.6 ± 18.9 years; 17 women) with CME were assessed. Underlying diseases associated with uveitis-related CME are juvenile idiopathic arthritis (n = 9), Behçet disease (n = 7), birdshot retinochoroidopathy (n = 4), idiopathic (n = 4), and sarcoidosis (n = 1). The ocular patterns were panuveitis (n = 9), anterior uveitis (n = 7), posterior uveitis (n = 5), and intermediate uveitis (n = 4). Most patients had CME in both eyes (n = 24). TCZ was used in monotherapy (n = 11) or combined with conventional immunosuppressive drugs. Regardless of the underlying disease, compared to baseline, a statistically significant improvement in macular thickness (415.7 ± 177.2 vs 259.1 ± 499.5 μm; P = .00009) and BCVA (0.39 ± 0.31 vs 0.54 ± 0.33; P = .0002) was obtained, allowing us to reduce the daily dose of prednisone (15.9 ± 13.6 mg/day vs 3.1 ± 2.3 mg/day; P = .002) after 12 months of therapy. Remission was achieved in 14 patients. Only minor side effects were observed after a mean follow-up of 12.7 ± 8.34 months. CONCLUSION: Macular thickness is reduced following administration of TCZ in refractory uveitis-related CME.
引用
- Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019. PMID: 30660771. doi:10.1016/j.ajo.2018.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。